Personal information

Japan

Activities

Employment (1)

Matsusaka Municipal Hospital: Matsusaka city, Mie, JP

2011-02 to present (Respiratory Center)
Employment
Source: Self-asserted source
Kentaro Ito

Works (18)

Physical Activity Using a Wearable Device as an Alternative to Performance Status in Patients With Advanced Lung Cancer

JAMA Oncology
2024-03-28 | Journal article
Part of ISSN: 2374-2437
Contributors: Kentaro Ito; Yuta Suzuki; Tadashi Sakaguchi; Kentaro Fujiwara; Yoichi Nishii; Hiroki Yasui; Osamu Taguchi; Osamu Hataji
Source: Self-asserted source
Kentaro Ito

Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial

eClinicalMedicine
2023-12 | Journal article
Contributors: Reiko Matsuzawa; Masahiro Morise; Kentaro Ito; Osamu Hataji; Kosuke Takahashi; Junji Koyama; Yachiyo Kuwatsuka; Yasuhiro Goto; Kazuyoshi Imaizumi; Hidetoshi Itani et al.
Source: check_circle
Crossref

Refractory response to entrectinib for ROS‐1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report

Thoracic Cancer
2023-09 | Journal article
Contributors: Kentaro Ito; Miho Nishio; Kentaro Fujiwara; Yoichi Nishii; Kengo Ushiro; Hiroki Yasui; Osamu Hataji
Source: check_circle
Crossref

Physical Activity Estimated by the Wearable Device in Lung Disease Patients: Exploratory Analyses of Prospective Observational Study.

Journal of clinical medicine
2023-06-30 | Journal article
Contributors: Ito K; Esumi M; Esumi S; Suzuki Y; Sakaguchi T; Fujiwara K; Nishii Y; Yasui H; Taguchi O; Hataji O
Source: Self-asserted source
Kentaro Ito

Data from Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

2023-03-31 | Preprint
Contributors: Yuta Adachi; Kentaro Ito; Yuko Hayashi; Ryo Kimura; Tuan Zea Tan; Rui Yamaguchi; Hiromichi Ebi
Source: check_circle
Crossref

Data from Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

2023-03-31 | Preprint
Contributors: Yuta Adachi; Kentaro Ito; Yuko Hayashi; Ryo Kimura; Tuan Zea Tan; Rui Yamaguchi; Hiromichi Ebi
Source: check_circle
Crossref

Supplementary Data from Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

2023-03-31 | Preprint
Contributors: Yuta Adachi; Kentaro Ito; Yuko Hayashi; Ryo Kimura; Tuan Zea Tan; Rui Yamaguchi; Hiromichi Ebi
Source: check_circle
Crossref

Supplementary Data from Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

2023-03-31 | Preprint
Contributors: Yuta Adachi; Kentaro Ito; Yuko Hayashi; Ryo Kimura; Tuan Zea Tan; Rui Yamaguchi; Hiromichi Ebi
Source: check_circle
Crossref

Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L

Cancer Science
2022-01 | Journal article
Contributors: Shinya Sakata; Kohei Otsubo; Hisako Yoshida; Kentaro Ito; Atsushi Nakamura; Shunsuke Teraoka; Naohisa Matsumoto; Yoshimasa Shiraishi; Koji Haratani; Motohiro Tamiya et al.
Source: check_circle
Crossref

A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903.

ESMO open
2021-05-10 | Journal article
Source: Self-asserted source
Kentaro Ito

Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study

European Journal of Cancer
2021-03 | Journal article
Contributors: Kentaro Ito; Takeharu Yamanaka; Hidetoshi Hayashi; Yoshihiro Hattori; Kazumi Nishino; Haruki Kobayashi; Yuko Oya; Toshihide Yokoyama; Takashi Seto; Koichi Azuma et al.
Source: check_circle
Crossref

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

Clinical Cancer Research
2020-11-15 | Journal article
Contributors: Yuta Adachi; Kentaro Ito; Yuko Hayashi; Ryo Kimura; Tuan Zea Tan; Rui Yamaguchi; Hiromichi Ebi
Source: check_circle
Crossref

Propensity score analysis of overall survival between first‐ and second‐generation EGFR‐TKIs using real‐world data

Cancer Science
2020-10 | Journal article
Contributors: Kentaro Ito; Kenta Murotani; Akihito Kubo; Eiji Kunii; Hirokazu Taniguchi; Joe Shindoh; Kazuhiro Asada; Kazuyoshi Imaizumi; Kosuke Takahashi; Masato Karayama et al.
Source: check_circle
Crossref

The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer

Lung Cancer
2019-02 | Journal article
Contributors: Kentaro Ito; Satoru Miura; Tadashi Sakaguchi; Kenta Murotani; Nobuyuki Horita; Hiroaki Akamatsu; Kohei Uemura; Satoshi Morita; Nobuyuki Yamamoto
Source: check_circle
Crossref

Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial.

Journal of Thoracic Disease
2018-09-01 | Journal article
Source: Self-asserted source
Kentaro Ito

Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non–Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice

Clinical Lung Cancer
2018-03 | Journal article
Contributors: Kentaro Ito; Yuta Suzuki; Haruko Saiki; Tadashi Sakaguchi; Kosuke Hayashi; Yoichi Nishii; Fumiaki Watanabe; Osamu Hataji
Source: check_circle
Crossref

Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
2016-08-04 | Journal article
Source: Self-asserted source
Kentaro Ito

"Pseudoprogression" of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
2016-05-14 | Journal article
Source: Self-asserted source
Kentaro Ito

Peer review (8 reviews for 4 publications/grants)

Review activity for Cancer immunology and immunotherapy. (1)
Review activity for Clinical lung cancer. (3)
Review activity for The Lancet regional health. (2)
Review activity for The Lancet. (2)